For Immediate Release 24 April 2008

The Medical House PLC

Annual Report and AGM Notice

Medical House plc (AIM: MLH), the drug delivery specialist, is pleased to announce that its annual report and accounts for the year ended 31 December 2007 has now been posted to shareholders and is also available on the Company’s website http://www.themedicalhouse.com.
.
-Ends-

For further information

The Medical House PLC
Bryan Bodek Deputy Chairman
and
Ian Townsend, Chairman
David Urquhart Managing Director
Tel: 0114 261 9011
www.themedicalhouse.com

Buchanan Communications
Tim Anderson / Rebecca Skye Dietrich
020 7466 5000

Nomura Code Securites Ltd
020 7776 1200
Richard Potts

Notes to Editors:

About The Medical House

There is a growing trend in the pharmaceutical industry towards the use of disposable autoinjectors, incorporating pre-filled syringes, which facilitate patient self-injection, as a means of creating competitive advantage for injectable drugs, including a number of significant new biologic products. TMH’s “ASI” autoinjector technology allows injections to be easily and safely undertaken by patients or by other non-clinicians such as family members and colleagues and are suitable for both elective therapies and emergency situations.

In November 2007, TMH announced that it has agreed to extend the term of the development, licensing and supply agreement for the ASI which it signed in December 2006 with a leading global pharmaceutical company. Under new terms, the minimum duration has been increased from five to six years, with TMH agreeing to a provision for further extension to approximately 16 years. Additionally, TMH’s projected revenues are increased from £27 million to £34 million (of which £23 million is for technology access, or licence, fees). TMH’s minimum guaranteed revenues have also increased to £20.5 million (of which £15 million is in licence fees). TMH is receiving £3 million of pre-commercialisation licence fees. TMH recently commenced work on the pre-commercial phase of the agreement’s development programme and this will result in additional development monies to TMH of approximately £900,000 over the next 18 months.

Also in November 2007, TMH announced that it has signed a strategic marketing agreement with Catalent Pharma Solutions (formerly the Pharmaceutical Technologies and Services segment of Cardinal Health, Inc), a leading global provider of advanced technologies and outsourcing services to pharmaceutical and biotechnology companies. Under the terms of this agreement, the companies will jointly promote and market TMH’s ASI system in combination with Catalent’s services and technologies, which include sterile filling of pre-filled syringes. Catalent offers extensive capabilities for the development, manufacture and packaging of pharmaceutical and biotechnology products, and brings to the collaboration extensive customer relationships in nearly 100 countries, and an experienced business development team operating in the world’s leading pharmaceutical markets. The companies are also exploring opportunities to jointly develop specific drug & device combination products, suitable for out-licensing and/or marketing partnerships with pharmaceutical industry partners.

TMH signed its first licensing deal for the ASI in June 2006 with Martindale Products and Specials, part of Cardinal Health Inc, in an initial five-year contract to supply the ASI system for use with an, as-yet, undisclosed pharmaceutical product, in the United Kingdom. The combined product is to incorporate TMH’s ASI and Martindale’s pre-filled syringe, The agreement has projected revenues for TMH of £3m over an initial supply period of 5 years.

In December 2005, TMH announced an agreement with a European Government Agency to develop a disposable autoinjector for emergency administration of specific pharmaceutical compounds, based on TMH’s ASI autoinjector. Within this project, TMH’s client is making the required capital investment and covering the costs of design and development. In March 2007, it was announced that TMH had been commissioned by this Agency to enter into a second phase of development within the project, which involves TMH developing and manufacturing devices, according to defined operational and functional requirements, for technical assessment, over an anticipated 12 months project duration. Within the second phase of the project, TMH will receive up to £1m, subject to achieving agreed milestones, in relation to the cost of the project including associated design and development activities.

In September 2004, TMH signed an agreement with Serono to develop and supply a new needle-free injector for use with its human growth hormone. This licence and supply agreement is for an initial period of 5 years with projected revenues for TMH of £4.3m.

For more information, visit www.themedicalhouse.com.